Stephen T Abedon

List of Publications by Citations

109 papers	5,617 citations	38 h-index	74 g-index
114 ext. papers	6,891 ext. citations	4.3 avg, IF	6.84 L-index

#	Paper	IF	Citations
109	Phage treatment of human infections. *Bacteriophage*, **2011**, 1, 66-85		577
108	Phage cocktails and the future of phage therapy. *Future Microbiology*, **2013**, 8, 769-83	2.9	484
107	Pros and cons of phage therapy. *Bacteriophage*, **2011**, 1, 111-114		451
106	Phage therapy in clinical practice: treatment of human infections. *Current Pharmaceutical Biotechnology*, **2010**, 11, 69-86	2.6	436
105	Bacteriophage host range and bacterial resistance. *Advances in Applied Microbiology*, **2010**, 70, 217-48	4.9	410
104	Lysogeny in nature: mechanisms, impact and ecology of temperate phages. *ISME Journal*, **2017**, 11, 1511-1520	11.5	272
103	Lysis from without. *Bacteriophage*, **2011**, 1, 46-49		201
102	Phage therapy pharmacology. *Current Pharmaceutical Biotechnology*, **2010**, 11, 28-47	2.6	171
101	Bacteriophage latent-period evolution as a response to resource availability. *Applied and Environmental Microbiology*, **2001**, 67, 4233-41	4.8	170
100	Phage therapy pharmacology phage cocktails. *Advances in Applied Microbiology*, **2012**, 78, 1-23	4.9	114
99	Bacteriophages and their enzymes in biofilm control. *Current Pharmaceutical Design*, **2015**, 21, 85-99	3.3	113
98	Experimental examination of bacteriophage latent-period evolution as a response to bacterial availability. *Applied and Environmental Microbiology*, **2003**, 69, 7499-506	4.8	110
97	Diversity of phage infection types and associated terminology: the problem with 'Lytic or lysogenic'. *FEMS Microbiology Letters*, **2016**, 363,	2.9	94
96	Kinetics of phage-mediated biocontrol of bacteria. *Foodborne Pathogens and Disease*, **2009**, 6, 807-15	3.8	94
95	Phage evolution and ecology. *Advances in Applied Microbiology*, **2009**, 67, 1-45	4.9	76
94	Phage therapy dosing: The problem(s) with multiplicity of infection (MOI). *Bacteriophage*, **2016**, 6, e1220348		65
93	Bacterial 'immunity' against bacteriophages. *Bacteriophage*, **2012**, 2, 50-54		65

92	The roles of the bacteriophage T4 r genes in lysis inhibition and fine-structure genetics: a new perspective. *Genetics*, **1998**, 148, 1539-50	4	63
91	Phage therapy of pulmonary infections. *Bacteriophage*, **2015**, 5, e1020260		62
90	Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria. *Pharmaceuticals*, **2015**, 8, 559-89	5.2	62
89	Bacteriophage plaques: theory and analysis. *Methods in Molecular Biology*, **2009**, 501, 161-74	1.4	60
88	Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets?. *FEMS Microbiology Letters*, **2016**, 363,	2.9	59
87	Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies. *Microbiology and Molecular Biology Reviews*, **2019**, 83,	13.2	59
86	Selection for lysis inhibition in bacteriophage. *Journal of Theoretical Biology*, **1990**, 146, 501-11	2.3	57
85	Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?. *Antibiotics*, **2019**, 8,	4.9	55
84	Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities. *Viruses*, **2012**, 4, 663-87	6.2	55
83	Phage "delay" towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages. *AIMS Microbiology*, **2017**, 3, 186-226	4.5	52
82	Bacteriophage prehistory: Is or is not Hankin, 1896, a phage reference?. *Bacteriophage*, **2011**, 1, 174-178		51
81	Optimizing bacteriophage plaque fecundity. *Journal of Theoretical Biology*, **2007**, 249, 582-92	2.3	51
80	Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. *Pharmaceuticals*, **2015**, 8, 525-58	5.2	48
79	Information Phage Therapy Research Should Report. *Pharmaceuticals*, **2017**, 10,	5.2	45
78	Bacteriophage secondary infection. *Virologica Sinica*, **2015**, 30, 3-10	6.4	42
77	Bacteriophage evolution given spatial constraint. *Journal of Theoretical Biology*, **2007**, 248, 111-9	2.3	41
76	Why Bacteriophage Encode Exotoxins and other Virulence Factors. *Evolutionary Bioinformatics*, **2005**, 1, 117693430500100	1.9	38
75	Bacteriophage T4 resistance to lysis-inhibition collapse. *Genetical Research*, **1999**, 74, 1-11	1.1	38

74	The murky origin of Snow White and her T-even dwarfs. *Genetics*, **2000**, 155, 481-6	4	38
73	Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent. *Microbiology Spectrum*, **2017**, 5,	8.9	34
72	Why bacteriophage encode exotoxins and other virulence factors. *Evolutionary Bioinformatics*, **2007** , 1, 97-110	1.9	34
71	Phage therapy: eco-physiological pharmacology. *Scientifica*, **2014**, 2014, 581639	2.6	32
70	Coming-of-Age Characterization of Soil Viruses: A User Guide to Virus Isolation, Detection within Metagenomes, and Viromics. *Soil Systems*, **2020**, 4, 23	3.5	30
69	Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections. *Advanced Drug Delivery Reviews*, **2019**, 145, 18-39	18.5	30
68	Look Who's Talking: T-Even Phage Lysis Inhibition, the Granddaddy of Virus-Virus Intercellular Communication Research. *Viruses*, **2019**, 11,	6.2	29
67	Smaller fleas: viruses of microorganisms. *Scientifica*, **2012**, 2012, 734023	2.6	27
66	Phage Therapy: Various Perspectives on How to Improve the Art. *Methods in Molecular Biology*, **2018**, 1734, 113-127	1.4	25
65	Commentary: Communication between Viruses Guides Lysis-Lysogeny Decisions. *Frontiers in Microbiology*, **2017**, 8, 983	5.7	25
64	Active bacteriophage biocontrol and therapy on sub-millimeter scales towards removal of unwanted bacteria from foods and microbiomes. *AIMS Microbiology*, **2017**, 3, 649-688	4.5	23
63	Envisaging bacteria as phage targets. *Bacteriophage*, **2011**, 1, 228-230		17
62	Thinking about microcolonies as phage targets. *Bacteriophage*, **2012**, 2, 200-204		17
61	Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. *Pharmaceuticals*, **2021**, 14,	5.2	16
60	Basic Phage Mathematics. *Methods in Molecular Biology*, **2018**, 1681, 3-30	1.4	16
59	Commentary: A Host-Produced Quorum-Sensing Autoinducer Controls a Phage Lysis-Lysogeny Decision. *Frontiers in Microbiology*, **2019**, 10, 1171	5.7	13
58	Communication Among Phages, Bacteria, and Soil Environments. *Soil Biology*, **2011**, 37-65	1	13
57	Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model. *Frontiers in Microbiology*, **2016**, 7, 1251	5.7	13

56	Phage Therapy: The Pharmacology of Antibacterial Viruses. *Current Issues in Molecular Biology*, **2021**, 40, 81-164	2.9	12
55	Bacteriophage-Mediated Biocontrol of Wound Infections, and Ecological Exploitation of Biofilms by Phages. *Recent Clinical Techniques, Results, and Research in Wounds*, **2018**, 121-158	0	11
54	Archaeal viruses, not archaeal phages: an archaeological dig. *Archaea*, **2013**, 2013, 251245	2	11
53	Phage population growth: constraints, games, adaptation64-93		11
52	Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.. *Antibiotics*, **2021**, 10,	4.9	11
51	Facilitation of CRISPR adaptation. *Bacteriophage*, **2011**, 1, 179-181		10
50	Phages, ecology, evolution1-28		10
49	Phage ecology of bacterial pathogenesis353-386		8
48	Modeling phage plaque growth415-438		8
47	Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?. *Pharmaceuticals*, **2021**, 14,	5.2	8
46	Modeling bacteriophage population growth389-414		7
45	Fighting Fire with Fire: Phage Potential for the Treatment of O157 Infection. *Antibiotics*, **2018**, 7,	4.9	7
44	Phages, bacteria, and food302-331		6
43	Phage-Phage, Phage-Bacteria, and Phage-Environment Communication **2020**, 23-70		5
42	Improving Phage-Biofilm In Vitro Experimentation. *Viruses*, **2021**, 13,	6.2	5
41	Virus ecology and disturbances: impact of environmental disruption on the viruses of microorganisms. *Frontiers in Microbiology*, **2014**, 5, 700	5.7	4
40	Phage Ecology and Bacterial Pathogenesis66-91		4
39	Impact of spatial structure on phage population growth94-113		3

38	Bacteriophage Ecology **2021**, 253-294		3
37	Are archaeons incapable of being parasites or have we simply failed to notice?. *BioEssays*, **2013**, 35, 501	4.1	2
36	Bacteriophage Ecology **2020**, 1-42		2
35	Friends or Foes? Rapid Determination of Dissimilar Colistin and Ciprofloxacin Antagonism of Phages. *Pharmaceuticals*, **2021**, 14,	5.2	2
34	An online phage therapy bibliography: separating under-indexed wheat from overly indexed chaff. *AIMS Microbiology*, **2017**, 3, 525-528	4.5	2
33	Detection of Bacteriophages: Phage Plaques **2018**, 1-32		2
32	Virus-Like Particle: Evolving Meanings in Different Disciplines. *Phage*, **2021**, 2, 11-15	1.8	2
31	In vitro analysis of colistin and ciprofloxacin antagonism of Pseudomonas aeruginosa phage PEV2 infection activities		1
30	Detection of Bacteriophages: Phage Plaques **2021**, 507-538		1
29	Bacteriophage Pharmacology and Immunology **2018**, 1-45		0
28	Bacteriophage Pharmacology and Immunology **2021**, 295-339		0
27	Pleiotropic Costs of Phage Resistance **2022**, 253-262		0
26	Salutary Contributions of Viruses to Medicine and Public Health **2012**, 389-405		
25	Bacteriophage Clinical Use as Antibacterial Drugs: Utility and Precedent **2018**, 417-451		
24	Brief Introduction to Phage Ecology **2022**, 41-52		
23	Concepts of Natural Selection in Light of Phage Exposure **2022**, 265-274		
22	Resistance to Phages, Part II: Bacteria Live! **2022**, 217-229		
21	A Closer Overview of Phage Infections **2022**, 15-27		

2 Resistance to Phages, Part I: Overview **2022**, 207-215

1 Domestication of Phage Genes **2022**, 193-203